Baxter’s Eptifibatide Receives the US FDA’s Approval for Cardiovascular Diseases

Shots:

• Baxter’s ready to use Eptifibatide is approved and launched for patients with acute coronary syndrome (ACS) & percutaneous coronary intervention (PCI)
• The FDA approval strengthens Baxter’s premix portfolio, enhance patient’s safety by avoiding dosing error and reduces the burden on hospital pharmacist
• Eptifibatide (75mg/100ml) is a platelet aggregation inhibitor, based on Baxter’s galaxy container technology that enhances the shelf life of premixed therapies, currently available in the US

Click here to read full press release/ article | Ref: Baxter| Image: The Baxter Bulletin